NCT02807116View on ClinicalTrials.gov

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Healthy Subjects
Interventions
DRUG

Pacritinib

Subjects received a single oral 400-mg dose of pacritinib

DRUG

Rifampin

Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period

DRUG

Pacritinib and Rifampin

On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.

Trial Locations (1)

32117

Covance Clinical Research Unit, Daytona Beach

Sponsors

Lead Sponsor

CTI BioPharma

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

CTI BioPharma

INDUSTRY

NCT02807116 - Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects | Biotech Hunter | Biotech Hunter